Your browser doesn't support javascript.
loading
Moving iPSC-Derived Cardiomyocytes Forward to Treat Myocardial Infarction.
Tu, Chengyi; Zoldan, Janet.
Affiliation
  • Tu C; Department of Biomedical Engineering, The University of Texas at Austin, Austin, TX 78712, USA.
  • Zoldan J; Department of Biomedical Engineering, The University of Texas at Austin, Austin, TX 78712, USA. Electronic address: zjanet@utexas.edu.
Cell Stem Cell ; 23(3): 322-323, 2018 09 06.
Article in En | MEDLINE | ID: mdl-30193131
ABSTRACT
Human pluripotent stem cell-derived cardiomyocytes represent a promising cell source for cardiac repair. However, their clinical translation is hindered by limited evidence for functional benefits in primate models, potential risks for arrhythmias, and teratoma formation. A recent study by Liu et al. (2018) makes significant progress on these critical issues.
Subject(s)
Fulltext
Add to My VHL
Print
XML
PubMed Links
Search on Google

Full text: 1 Collection: 01-internacional Database: MEDLINE Main subject: Induced Pluripotent Stem Cells / Human Embryonic Stem Cells / Myocardial Infarction Limits: Animals / Humans Language: En Journal: Cell Stem Cell Year: 2018 Document type: Article Affiliation country: United States
Fulltext
Add to My VHL
Print
XML
PubMed Links
Search on Google

Full text: 1 Collection: 01-internacional Database: MEDLINE Main subject: Induced Pluripotent Stem Cells / Human Embryonic Stem Cells / Myocardial Infarction Limits: Animals / Humans Language: En Journal: Cell Stem Cell Year: 2018 Document type: Article Affiliation country: United States